Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization.
Cumming, J., Babu, S., Huang, Y., Carrol, C., Chen, X., Favreau, L., Greenlee, W., Guo, T., Kennedy, M., Kuvelkar, R., Le, T., Li, G., McHugh, N., Orth, P., Ozgur, L., Parker, E., Saionz, K., Stamford, A., Strickland, C., Tadesse, D., Voigt, J., Zhang, L., Zhang, Q.(2010) Bioorg Med Chem Lett 20: 2837-2842
- PubMed: 20347593 
- DOI: https://doi.org/10.1016/j.bmcl.2010.03.050
- Primary Citation of Related Structures:  
3LNK, 3LPI, 3LPJ, 3LPK - PubMed Abstract: 
With collaboration between chemistry, X-ray crystallography, and molecular modeling, we designed and synthesized a series of novel piperazine sulfonamide BACE1 inhibitors. Iterative exploration of the non-prime side and S2' sub-pocket of the enzyme culminated in identification of an analog that potently lowers peripheral Abeta(40) in transgenic mice with a single subcutaneous dose.
Organizational Affiliation: 
Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. jared.cumming@merck.com